Genmab GNMSF Stock
Genmab Price Chart
Genmab GNMSF Financial and Trading Overview
| Genmab stock price | 555.3 USD |
| Previous Close | 580 USD |
| Open | 445 USD |
| Bid | 551.25 USD x 100 |
| Ask | 572 USD x 200 |
| Day's Range | 445 - 581 USD |
| 52 Week Range | 232.34 - 581 USD |
| Volume | 397 USD |
| Avg. Volume | 2.23K USD |
| Market Cap | 34.15B USD |
| Beta (5Y Monthly) | 0.645 |
| PE Ratio (TTM) | 43.86256 |
| EPS (TTM) | 12.66 USD |
| Forward Dividend & Yield | N/A (0%) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GNMSF Valuation Measures
| Enterprise Value | 36.92B USD |
| Trailing P/E | 43.86256 |
| Forward P/E | 40.180897 |
| PEG Ratio (5 yr expected) | 7.23 |
| Price/Sales (ttm) | 8.265683 |
| Price/Book (mrq) | 5.5652432 |
| Enterprise Value/Revenue | 8.936 |
| Enterprise Value/EBITDA | 26.808 |
Trading Information
Genmab Stock Price History
| Beta (5Y Monthly) | 0.645 |
| 52-Week Change | 96.14% |
| S&P500 52-Week Change | 13.16% |
| 52 Week High | 581 USD |
| 52 Week Low | 232.34 USD |
| 50-Day Moving Average | 365.79 USD |
| 200-Day Moving Average | 303.21 USD |
GNMSF Share Statistics
| Avg. Volume (3 month) | 2.23K USD |
| Avg. Daily Volume (10-Days) | 5.54K USD |
| Shares Outstanding | 61.49M |
| Float | 55.29M |
| Short Ratio | N/A |
| % Held by Insiders | 1.11% |
| % Held by Institutions | 47.15% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 19.07% |
| Operating Margin (ttm) | 35.23% |
| Gross Margin | 93.02% |
| EBITDA Margin | 33.33% |
Management Effectiveness
| Return on Assets (ttm) | 8.78% |
| Return on Equity (ttm) | 13.99% |
Income Statement
| Revenue (ttm) | 4.13B USD |
| Revenue Per Share (ttm) | 67.06 USD |
| Quarterly Revenue Growth (yoy) | 24.89% |
| Gross Profit (ttm) | 3.84B USD |
| EBITDA | 1.38B USD |
| Net Income Avi to Common (ttm) | 788M USD |
| Diluted EPS (ttm) | 12.66 |
| Quarterly Earnings Growth (yoy) | -9.80% |
Balance Sheet
| Total Cash (mrq) | 1.51B USD |
| Total Cash Per Share (mrq) | 25.29 USD |
| Total Debt (mrq) | 5.27B USD |
| Total Debt/Equity (mrq) | 88.52 USD |
| Current Ratio (mrq) | 2.457 |
| Book Value Per Share (mrq) | 99.78 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 891M USD |
| Levered Free Cash Flow (ttm) | 870.63M USD |
Profile of Genmab
| Country | United States |
| State | N/A |
| City | Copenhagen |
| Address | Carl Jacobsens Vej 30 |
| ZIP | 2500 |
| Phone | 45 70 20 27 28 |
| Website | https://www.genmab.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 3119 |
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Q&A For Genmab Stock
What is a current GNMSF stock price?
Genmab GNMSF stock price today per share is 555.3 USD.
How to purchase Genmab stock?
You can buy GNMSF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Genmab?
The stock symbol or ticker of Genmab is GNMSF.
Which industry does the Genmab company belong to?
The Genmab industry is Biotechnology.
How many shares does Genmab have in circulation?
The max supply of Genmab shares is 61.49M.
What is Genmab Price to Earnings Ratio (PE Ratio)?
Genmab PE Ratio is 43.86256000 now.
What was Genmab earnings per share over the trailing 12 months (TTM)?
Genmab EPS is 12.66 USD over the trailing 12 months.
Which sector does the Genmab company belong to?
The Genmab sector is Healthcare.
